Christopher R. Cline - 01 Sep 2022 Form 3 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role: Chief Financial Officer
Signature: /s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol: TVTX
Transactions as of: 01 Sep 2022
Net transactions value: $0
Form type: 3
Filing time: 01 Sep 2022, 18:19:00 UTC
Next filing: 26 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	TVTX	Common Stock						28,723	01 Sep 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TVTX	Employee Stock Option (Right to Buy)							01 Sep 2022	Common Stock	40,000	$12.51	Direct	F1
holding	TVTX	Employee Stock Option (Right to Buy)							01 Sep 2022	Common Stock	15,000	$32.49	Direct	F1
holding	TVTX	Employee Stock Option (Right to Buy)							01 Sep 2022	Common Stock	20,000	$16.23	Direct	F1
holding	TVTX	Employee Stock Option (Right to Buy)							01 Sep 2022	Common Stock	20,000	$17.44	Direct	F1
holding	TVTX	Employee Stock Option (Right to Buy)							01 Sep 2022	Common Stock	12,500	$25.25	Direct	F1
holding	TVTX	Employee Stock Option (Right to Buy)							01 Sep 2022	Common Stock	10,000	$17.96	Direct	F2
holding	TVTX	Employee Stock Option (Right to Buy)							01 Sep 2022	Common Stock	12,500	$15.46	Direct	F3
holding	TVTX	Employee Stock Option (Right to Buy)							01 Sep 2022	Common Stock	16,250	$26.88	Direct	F4
holding	TVTX	Employee Stock Option (Right to Buy)							01 Sep 2022	Common Stock	17,500	$27.50	Direct	F5
holding	TVTX	Employee Stock Option (Right to Buy)							01 Sep 2022	Common Stock	5,000	$28.55	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option is fully vested and exercisable.
F2	One-fourth of the shares subject to the stock option vested and become exercisable on May 9, 2020, and the remaining shares vest in 36 equal monthly installments thereafter.
F3	One-fourth of the shares subject to the stock option vested and become exercisable on January 31, 2021, and the remaining shares vest in 36 equal monthly installments thereafter.
F4	One-fourth of the shares subject to the stock option vested and became exercisable on January 21, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
F5	One-fourth of the shares subject to the stock option will vest and become exercisable on January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.
F6	One-fourth of the shares subject to the stock option will vest and become exercisable on April 10, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.